122 related articles for article (PubMed ID: 37634829)
1. Epitope mapping of nanobodies binding the Alzheimer's disease receptor SORLA.
Monti G; Vincke C; Lunding M; Jensen AMG; Madsen P; Muyldermans S; Kjolby M; Andersen OM
J Biotechnol; 2023 Sep; 375():17-27. PubMed ID: 37634829
[TBL] [Abstract][Full Text] [Related]
2. Characterization of nanobodies binding human fibrinogen selected by E. coli display.
Salema V; López-Guajardo A; Gutierrez C; Mencía M; Fernández LÁ
J Biotechnol; 2016 Sep; 234():58-65. PubMed ID: 27485813
[TBL] [Abstract][Full Text] [Related]
3. Generation, biochemical characterizations and validation of potent nanobodies derived from alpaca specific for human receptor of advanced glycation end product.
Mohammed A; Zeng W; Mengist HM; Kombe Kombe AJ; Ou H; Yang Y; Dan Z; Xu Z; Ma H; Jin T
Biochem Biophys Res Commun; 2021 Dec; 581():38-45. PubMed ID: 34653677
[TBL] [Abstract][Full Text] [Related]
4. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
5. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ
MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381
[TBL] [Abstract][Full Text] [Related]
6. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
7. SORLA attenuates EphA4 signaling and amyloid β-induced neurodegeneration.
Huang TY; Zhao Y; Jiang LL; Li X; Liu Y; Sun Y; Piña-Crespo JC; Zhu B; Masliah E; Willnow TE; Pasquale EB; Xu H
J Exp Med; 2017 Dec; 214(12):3669-3685. PubMed ID: 29114064
[TBL] [Abstract][Full Text] [Related]
8. HSPA12A targets the cytoplasmic domain and affects the trafficking of the Amyloid Precursor Protein receptor SorLA.
Madsen P; Isaksen TJ; Siupka P; Tóth AE; Nyegaard M; Gustafsen C; Nielsen MS
Sci Rep; 2019 Jan; 9(1):611. PubMed ID: 30679749
[TBL] [Abstract][Full Text] [Related]
9. The adaptor protein PICK1 targets the sorting receptor SorLA.
Binkle L; Klein M; Borgmeyer U; Kuhl D; Hermey G
Mol Brain; 2022 Feb; 15(1):18. PubMed ID: 35183222
[TBL] [Abstract][Full Text] [Related]
10. High yield purification of nanobodies from the periplasm of E. coli as fusions with the maltose binding protein.
Salema V; Fernández LÁ
Protein Expr Purif; 2013 Sep; 91(1):42-8. PubMed ID: 23856605
[TBL] [Abstract][Full Text] [Related]
11. Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins.
Veugelen S; Dewilde M; De Strooper B; Chávez-Gutiérrez L
Methods Enzymol; 2017; 584():59-97. PubMed ID: 28065273
[TBL] [Abstract][Full Text] [Related]
12. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein.
Gustafsen C; Glerup S; Pallesen LT; Olsen D; Andersen OM; Nykjær A; Madsen P; Petersen CM
J Neurosci; 2013 Jan; 33(1):64-71. PubMed ID: 23283322
[TBL] [Abstract][Full Text] [Related]
13. Development and Characterization of Nanobodies Targeting the Kupffer Cell.
Zheng F; Zhou J; Ouyang Z; Zhang J; Wang X; Muyldermans S; Van Ginderachter J; Devoogdt N; Wen Y; Schoonooghe S; Raes G
Front Immunol; 2021; 12():641819. PubMed ID: 33692811
[TBL] [Abstract][Full Text] [Related]
14. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Roles of Sortilin and SorLA in Immune-Related Processes.
Talbot H; Saada S; Naves T; Gallet PF; Fauchais AL; Jauberteau MO
Front Pharmacol; 2018; 9():1507. PubMed ID: 30666202
[TBL] [Abstract][Full Text] [Related]
16. Exploring the sortilin related receptor, SorLA, in depression.
Buttenschøn HN; Elfving B; Nielsen M; Skeldal S; Kaas M; Mors O; Glerup S
J Affect Disord; 2018 May; 232():260-267. PubMed ID: 29499509
[TBL] [Abstract][Full Text] [Related]
17. Characterization of camel nanobodies specific for superfolder GFP fusion proteins.
Twair A; Al-Okla S; Zarkawi M; Abbady AQ
Mol Biol Rep; 2014 Oct; 41(10):6887-98. PubMed ID: 25085037
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity Risk Profile of Nanobodies.
Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
Front Immunol; 2021; 12():632687. PubMed ID: 33767701
[TBL] [Abstract][Full Text] [Related]
19. Versatile Application of Nanobodies for Food Allergen Detection and Allergy Immunotherapy.
Hu Y; Wang Y; Lin J; Wu S; Muyldermans S; Wang S
J Agric Food Chem; 2022 Jul; 70(29):8901-8912. PubMed ID: 35820160
[TBL] [Abstract][Full Text] [Related]
20. Applications of nanobodies in brain diseases.
Zheng F; Pang Y; Li L; Pang Y; Zhang J; Wang X; Raes G
Front Immunol; 2022; 13():978513. PubMed ID: 36426363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
